Various topical drug combination assessed using a neurosensory stent for chronic intraoral neuropathic pain: a pilot study

Chronic intraoral neuropathic pain (NP), often developing post-dental procedures, poses significant management challenges. The prevalent use of systemic treatments, with their frequent substantial side effects, emphasizes the need for alternative therapeutic strategies. Our aim is to explore the efficacy and adherence with a topical drug regimen delivered through a neurosensory stent (NS) for treating chronic neuropathic pain (NP) within the oral cavity. A retrospective analysis in addition to a telephone structured questionnaire conducted on patients with chronic intraoral NP treated at the Orofacial Pain Clinic, Hadassah Medical Center, between 2017 and 2020. A standard combination of lidocaine 2%, pregabalin 5%, ibuprofen 5% and optionally amitriptyline 2% was administered using a custom-made NS. Out of 12 participants, 6 reported more than 50% pain relief, indicating high effectiveness. Notably, females showed a more favorable response than males. 75% of patients used the NS consistently. No significant difference in pain relief was observed between the standard formula and the one with supplementary amitriptyline. The results highlight the potential of NS as an alternative, or adjunct treatment that may reduce the dosage of systemic medications for chronic NP. Additionally, the NS device can be used as an “escape drug”, or add-on, method if pain exacerbates under systemic therapy or if higher dose of systemic therapy causes serious side effects. Large scale prospective double-blind studies are required to substantiate the findings of this pilot study.

Neuropathic pain; Topical treatment; Oral pain; Neurosensory stent

[1] Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice ASC, et al. A new definition of neuropathic pain. Pain. 2011; 152: 2204–2205.

[2] Eliav T, Benoliel R, Korczeniewska OA. Post-traumatic trigeminal neuropathy: neurobiology and pathophysiology. Biology. 2024; 13: 167.

[3] Benoliel R, Gaul C. Persistent idiopathic facial pain. Cephalalgia. 2017; 37: 680–691.

[4] Baad-Hansen L, Benoliel R. Neuropathic orofacial pain: facts and fiction. Cephalalgia. 2017; 37: 670–679.

[5] Bouhassira D. Neuropathic pain: definition, assessment and epidemiology. Revue Neurologique. 2019; 175: 16–25.

[6] Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The neuropathic pain: an overview of the current treatment and future therapeutic approaches. International Journal of Immunopathology and Pharmacology. 2019; 33: 205873841983838.

[7] Haviv Y, Zadik Y, Sharav Y, Benoliel R. Painful traumatic trigeminal neuropathy: an open study on the pharmacotherapeutic response to stepped treatment. Journal of Oral & Facial Pain and Headache. 2014; 28: 52–60.

[8] Sharav Y, Heiliczer S, Benoliel R, Haviv Y. Pharmacological topical therapy for intra-oral post traumatic trigeminal neuropathic pain: a comprehensive review. Pharmaceuticals. 2024; 17: 264.

[9] Guilherme VA, Ribeiro LNM, Tofoli GR, Franz-Montan M, de Paula E, de Jesus MB. Current challenges and future of lipid nanoparticles formulations for topical drug application to oral mucosa, skin, and eye. To be published in Current Pharmaceutical Design. 2017. [Preprint].

[10] Kienzler J, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium Gel 1% versus oral diclofenac sodium in healthy volunteers. The Journal of Clinical Pharmacology. 2010; 50: 50–61.

[11] Heir G, Karolchek S, Kalladka M, Vishwanath A, Gomes J, Khatri R, et al. Use of topical medication in orofacial neuropathic pain: a retrospective study. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2008; 105: 466–469.

[12] Czerninski R, Pikovsky A, Gati I, Friedman M, Steinberg D. Comparison of the efficacy of a novel sustained release clotrimazole varnish and clotrimazole troches for the treatment of oral candidiasis. Clinical Oral Investigations. 2015; 19: 467–473.

[13] Sommer C, Cruccu G. Topical treatment of peripheral neuropathic pain: applying the evidence. Journal of Pain and Symptom Management. 2017; 53: 614–629.

[14] Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007; 132: 237–251.

[15] Chinna Reddy P, Chaitanya KS, Madhusudan Rao Y. A review on bioadhesive buccal drug delivery systems: current status of formulation and evaluation methods. Daru: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2011; 19: 385–403.

[16] Ivarsson D, Wahlgren M. Comparison of in vitro methods of measuring mucoadhesion: ellipsometry, tensile strength and rheological measurements. Colloids and Surfaces B: Biointerfaces. 2012; 92: 353–359.

[17] Bavarian R, Khawaja SN, Treister NS. Oral appliances in the management of neuropathic orofacial pain: a retrospective case series. Oral Diseases. 2022; 28: 805–812.

[18] Plaza-Villegas F, Heir G, Markman S, Khan J, Noma N, Benoliel R, et al. Topical pregabalin and diclofenac for the treatment of neuropathic orofacial pain in rats. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2012; 114: 449–456.

[19] Sivertsen B, Lallukka T, Petrie KJ, Steingrímsdóttir ÓA, Stubhaug A, Nielsen CS. Sleep and pain sensitivity in adults. Pain. 2015; 156: 1433–1439.

[20] Argoff CE. Topical analgesics in the management of acute and chronic pain. Mayo Clinic Proceedings. 2013; 88: 195–205.

[21] Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Current Medical Research and Opinion. 2009; 25: 1677–1687.

[22] Heir GM, Katzmann G, Covalesky B, Cammarata J, Mangal J, Kalladka M, et al. Use of compounded topical medications for treatment of orofacial pain: a narrative review. Journal of Oral and Maxillofacial Anesthesia. 2022; 1: 27.

[23] Haviv Y, Rettman A, Aframian D, Sharav Y, Benoliel R. Myofascial pain: an open study on the pharmacotherapeutic response to stepped treatment with tricyclic antidepressants and gabapentin. Journal of Oral & Facial Pain and Headache. 2015; 29: 144–151.

[24] International classification of orofacial pain, 1st edition (ICOP). Cephalalgia. 2020; 40: 129–221.

[25] Zur E. Topical treatment of neuropathic pain using compounded medications. The Clinical Journal of Pain. 2014; 30: 73–91.

[26] Padilla M, Clark GT, Merrill RL. Topical medications for orofacial neuropathic pain: a review. The Journal of the American Dental Association. 2000; 131: 184–195.

[27] Nasri-Heir C, Khan J, Heir GM. Topical medications as treatment of neuropathic orofacial pain. Dental Clinics of North America. 2013; 57: 541–553.

[28] Haribabu PK, Eliav E, Heir GM. Topical medications for the effective management of neuropathic orofacial pain. The Journal of the American Dental Association. 2013; 144: 612–614.

[29] Katz NP, Mou J, Paillard FC, Turnbull B, Trudeau J, Stoker M. Predictors of response in patients with postherpetic neuralgia and HIV-associated neuropathy treated with the 8% capsaicin patch (Qutenza). The Clinical Journal of Pain. 2015; 31: 859–866.

[30] Almoznino G, Barsheshet S, Mazor S, Yanko R, Sharav Y, Haviv Y. Long-term adherence to oral stabilization splints: does pain matter? Quintessence International. 2021; 53: 68–76.

[31] Sharav Y, Haviv Y, Tal M. Placebo or nocebo interventions as affected by hypnotic susceptibility. Applied Sciences. 2023; 13: 931.

[32] Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. The Journal of Clinical Pharmacology. 2003; 43: 111–117.